| Targeting oncogenic mutant p53 for cancer therapy A Parrales, T Iwakuma Frontiers in oncology 5, 288, 2015 | 362 | 2015 |
| Mutant p53 suppresses innate immune signaling to promote tumorigenesis M Ghosh, S Saha, J Bettke, R Nagar, A Parrales, T Iwakuma, ... Cancer cell 39 (4), 494-508. e5, 2021 | 214 | 2021 |
| DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway A Parrales, A Ranjan, SV Iyer, S Padhye, SJ Weir, A Roy, T Iwakuma Nature cell biology 18 (11), 1233-1243, 2016 | 207 | 2016 |
| p53 as a regulator of lipid metabolism in cancer A Parrales, T Iwakuma International journal of molecular sciences 17 (12), 2074, 2016 | 105 | 2016 |
| The interplay between mutant p53 and the mevalonate pathway A Parrales, E Thoenen, T Iwakuma Cell Death & Differentiation 25 (3), 460-470, 2018 | 92 | 2018 |
| ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation A Parrales, E López, I Lee-Rivera, AM López-Colomé Cellular Signalling 25 (4), 829-838, 2013 | 50 | 2013 |
| Thrombin stimulates RPE cell proliferation by promoting c‐Fos‐mediated cyclin D1 expression A Parrales, JP Palma‐Nicolás, E López, AM López‐Colomé Journal of cellular physiology 222 (2), 302-312, 2010 | 44 | 2010 |
| Thrombin activation of PI3K/PDK1/Akt signaling promotes cyclin D1 upregulation and RPE cell proliferation A Parrales, E Lopez, AM Lopez-Colome Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1813 (10), 1758-1766, 2011 | 41 | 2011 |
| Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression SV Iyer, A Ranjan, HK Elias, A Parrales, H Sasaki, BC Roy, S Umar, ... Nature Communications 7 (1), 13561, 2016 | 33 | 2016 |
| Comparative oncology approach to drug repurposing in osteosarcoma A Parrales, P McDonald, M Ottomeyer, A Roy, FJ Shoenen, M Broward, ... PLoS One 13 (3), e0194224, 2018 | 30 | 2018 |
| Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities SV Iyer, A Parrales, P Begani, A Narkar, AS Adhikari, LA Martinez, ... Oncotarget 7 (5), 5401, 2016 | 29 | 2016 |
| DNAJA1 promotes cancer metastasis through interaction with mutant p53 A Kaida, S Yamamoto, A Parrales, ED Young, A Ranjan, MA Alalem, ... Oncogene 40 (31), 5013-5025, 2021 | 22 | 2021 |
| Mutant p53 depletion by novel inhibitors for HSP40/J-domain proteins derived from the natural compound plumbagin M Alalem, M Bhosale, A Ranjan, S Yamamoto, A Kaida, S Nishikawa, ... Cancers 14 (17), 4187, 2022 | 11 | 2022 |
| Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB A Parrales, A Ranjan, T Iwakuma Stem cell investigation 4, 2017 | 11 | 2017 |
| Thrombin promotes the expression of Ccnd1 gene in RPE cells through the activation of converging signaling pathways I Lee-Rivera, E López, A Parrales, A Alvarez-Arce, AM López-Colomé Experimental eye research 139, 81-89, 2015 | 11 | 2015 |
| DNAJA1-and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen S Nishikawa, A Kaida, A Parrales, A Ranjan, M Alalem, H Ren, ... Cell Death Discovery 8 (1), 437, 2022 | 7 | 2022 |
| Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 2015; 5: 288 A Parrales, T Iwakuma | 6 | 2015 |
| Perinucleolar compartment (PNC) prevalence as an independent prognostic factor in pediatric ewing sarcoma: a multi-institutional study E Gonzalez, AA Ahmed, L McCarthy, K Chastain, S Habeebu, ... Cancers 15 (8), 2230, 2023 | 3 | 2023 |
| TAp63–miRNA–AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma A Parrales, T Iwakuma Cancer research 80 (12), 2439-2440, 2020 | 1 | 2020 |
| Abstract LB303: Suppression of stress granule formation is a novel vulnerability imposed by mutant p53 E Thoenen, A Ranjan, A Parrales, S Nishikawa, D Dixon, S Oka, ... Cancer Research 84 (7_Supplement), LB303-LB303, 2024 | | 2024 |
